VANCOUVER, British Columbia, Dec. 06, 2018 (GLOBE NEWSWIRE) -- NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) outlining the terms for the manufacturing & distribution of sub-lingual CBD tablets, based on NeutriSci’s proprietary sublingual tablet formulations, with LaSanta Botanicals Ltd., a privately held company based in Calgary, Alberta, with operations in Bogota, Colombia (the “Licensee”). The Licensee is licensed in Colombia to cultivate cannabis and to manufacture and export cannabis extracts.
Subject to the terms outlined in the MOU, NeutriSci will provide the Licensee with exclusive rights for Mexico, Central America, and South America, to utilize the NeutriSci technologies such that the licensee can produce and market sub-lingual CBD tablets. The tablets are a quick dissolving, flavored tablet that offer a method to provide the consumer with a measured dose of known CBD product.
Upon signing of a definitive agreement, the Licensee will pay NeutriSci a one-time licencing fee, and quarterly royalties based on the value of each unit sold. The licensee intends to market the product within its own network as well as through third party distributors. As part of the MOU, the Licensee may also supply NeutriSci with CBD when all legal requirements are met.
NeutriSci CEO, Glen Rehman stated, “This MOU establishes the next international product manufacturing and distribution deal utilizing our patent pending technologies. Together with the Licensee, we are very excited to be working towards launching the first of its kind quick dissolving CBD tablet in South America. This agreement represents another step towards achieving the international distribution of our products and IP. NeutriSci is also excited that once all legal requirements are met it will be able to access low-cost, high quality CBD compounds for distribution with its global partners.”
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO
NeutriSci International Inc.
Tel: (403) 264-6320
Email: info@neutrisci.com
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries.
Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.
For more information, please visit: www.neutrisci.com.
About LaSanta Botanicals
LaSanta is a pharmaceutical company with management in Canada and Colombia and is licensed in Colombia to cultivate cannabis and manufacture and export cannabis extracts and genetics. The company is combining agricultural and scientific expertise with product branding and distribution know-how to service legal cannabis markets in Colombia and around the world.
LaSanta produces low cost, premium-quality, organic medical cannabis using craft growing, all-natural principles. The company has a world-class genetic bank and has partnered with a leading Colombia university to perform independent laboratory testing of its extracts to ensure patients have access to a standardized, safe and consistent product.
For more information, please visit: www.lasanta.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.